TABLE 5.
Top 20 highly enriched pathways.
| ID | Pathways | Count | PValue | Genes |
|---|---|---|---|---|
| hsa04151 | PI3K-Akt signaling pathway | 10 | 2.48E-10 | CSF1R, HSP90AA1, ERBB3, PIK3CA, ERBB4, ERBB2, KRAS, EGFR, MTOR, MCL1 |
| hsa04012 | ErbB signaling pathway | 8 | 1.35E-11 | MAPK8, ERBB3, PIK3CA, ERBB4, ERBB2, KRAS, EGFR, MTOR |
| hsa05206 | MicroRNAs in cancer | 8 | 1.16E-07 | ABCB1, ERBB3, PIK3CA, ERBB2, KRAS, EGFR, MTOR, MCL1 |
| hsa05200 | Pathways in cancer | 8 | 4.40E-06 | CSF1R, HSP90AA1, MAPK8, PIK3CA, ERBB2, KRAS, EGFR, MTOR |
| hsa05205 | Proteoglycans in cancer | 7 | 2.59E-07 | ERBB3, PIK3CA, ERBB4, ERBB2, KRAS, EGFR, MTOR |
| hsa04010 | MAPK signaling pathway | 7 | 2.50E-06 | CSF1R, MAPK8, ERBB3, ERBB4, ERBB2, KRAS, EGFR |
| hsa05212 | Pancreatic cancer | 6 | 6.38E-08 | MAPK8, PIK3CA, ERBB2, KRAS, EGFR, MTOR |
| hsa01521 | EGFR tyrosine kinase inhibitor resistance | 6 | 7.74E-08 | ERBB3, PIK3CA, ERBB2, KRAS, EGFR, MTOR |
| hsa05215 | Prostate cancer | 6 | 2.16E-07 | HSP90AA1, PIK3CA, ERBB2, KRAS, EGFR, MTOR |
| hsa01522 | Endocrine resistance | 6 | 2.27E-07 | MAPK8, PIK3CA, ERBB2, KRAS, EGFR, MTOR |
| hsa05226 | Gastric cancer | 6 | 1.80E-06 | ABCB1, PIK3CA, ERBB2, KRAS, EGFR, MTOR |
| hsa05207 | Chemical carcinogenesis - receptor activation | 6 | 1.06E-05 | HSP90AA1, PIK3CA, KRAS, CYP3A4, EGFR, MTOR |
| hsa05230 | Central carbon metabolism in cancer | 5 | 2.97E-06 | PIK3CA, ERBB2, KRAS, EGFR, MTOR |
| hsa05210 | Colorectal cancer | 5 | 6.72E-06 | MAPK8, PIK3CA, KRAS, EGFR, MTOR |
| hsa05231 | Choline metabolism in cancer | 5 | 1.12E-05 | MAPK8, PIK3CA, KRAS, EGFR, MTOR |
| hsa05224 | Breast cancer | 5 | 5.50E-05 | PIK3CA, ERBB2, KRAS, EGFR, MTOR |
| hsa04014 | Ras signaling pathway | 5 | 3.46E-04 | CSF1R, MAPK8, PIK3CA, KRAS, EGFR |
| hsa05213 | Endometrial cancer | 4 | 8.55E-05 | PIK3CA, ERBB2, KRAS, EGFR |
| hsa05221 | Acute myeloid leukemia | 4 | 1.31E-04 | CSF1R, PIK3CA, KRAS, MTOR |
| hsa05223 | Non-small cell lung cancer | 4 | 1.62E-04 | PIK3CA, ERBB2, KRAS, EGFR |